ALSO IN THIS MONTH'S ISSUE

• Democratic And Republican Health Priorities In The Next Administration

  With the conventions and a contentious summer behind them, both political parties are laying out their agendas for the next four years. What are the Democratic and Republican health priorities?

• Companies To Watch: CalciMedica

  “In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.

• Drug Pricing Reform Twists And Turns In The COVID-19 Era

  At a time of newfound public trust in the pharmaceutical industry, there may be a unique opportunity for the industry to reshape the drug pricing reform debate and draw attention to the need for continued innovation.

• The Holy Grail: Bringing A Vaccine To Market … Soon

  The U.S. continues to be plagued by policy and operational failures. We need to embed policies to control the pandemic now.

• Building A Biotech: The Third Key Ingredient Beyond Innovation & Funding

  I would argue that if biotech organizations, at the R&D stage in particular, cannot successfully manage their communications practices, they are much more likely to fail regardless of the merits of their innovative technology or ability to secure funding.